MRNA chains contained in a modern coronavirus vaccine such as the trans-amplifying mRNA vaccine described in this article.
Credit: MikeMareen / iStock / Getty Images Plus

A new type of mRNA vaccine has been developed by researchers at the University of Pittsburgh and Pennsylvania State University that is more effective and cheaper to develop than vaccines currently on the market.

The vaccine is still at an early stage and is yet to be tested in humans, but the researchers believe their prototype vaccine could help drug developers and health authorities respond more quickly to new pathogens or to new variants of known pathogens such as the SARS-CoV-2 virus or different strains of influenza.

During and after the COVID-19 pandemic five different strains of SARS-CoV-2 emerged— Alpha, Beta, Gamma, Delta, and Omicron—making existing vaccines less effective.

“The emergence of novel variants that compromise vaccine immunity presents a significant challenge, requiring continuous evaluation of vaccine efficacy, and regular updates to maintain effectiveness,” write lead author Suresh Kuchipudi, PhD, a professor at the University of Pittsburgh, and colleagues in npj Vaccines.

“While updated booster shots have been developed to include additional S protein mRNAs to match circulating variants, they are often less effective since new variants have already emerged by the time they are ready for deployment. Additionally, the limited coverage of booster shots post-primary vaccination contributes to vaccine ineffectiveness, leaving a significant portion of the global population vulnerable to reinfection.”

Kuchipudi and colleagues have developed what they call a trans-amplifying mRNA vaccine encoding a spike protein from the SARS-CoV-2 virus. There are two types of amplifying mRNA vaccines that carry their own replicating enzyme (replicase), self-amplifying and trans-amplifying.

“The key distinction lies in the administration of replicase, with trans-amplifying mRNA vaccines delivering it as a separate mRNA (trans) from the one coding for the gene of interest, while self-amplifying mRNA vaccines deliver the replicase on the same mRNA (cis or self) as the gene of interest,” explain the authors.

The trans-amplifying mRNA vaccine the team created was tested in mice and the researchers found that neutralizing antibody levels triggered by the vaccine were similar to approved mRNA vaccines, but the amount of mRNA used was up to 40 times lower.

In a test against an Omicron strain of SARS-CoV-2, the new vaccine reduced the amount of virus in the mouse lungs by more than 10-fold and also induced antibodies against various different variants of the virus.

“This has the potential for more lasting immunity that would not require updating, because the vaccine has the potential to provide broad protection,” said Kuchipudi in a press statement. “Additionally, this format requires an mRNA dose 40 times less than conventional vaccines, so this new approach significantly reduces the overall cost of the vaccine.”

Also of Interest